News Sentiment

MOLN sentiment intelligence

Molecular Partners AG ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.02 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+1.1% over one week, -2.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction 1.1% Price digesting
Trend fit Trend inactive -2.1% over four weeks
Fair value -12.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 31
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 7
TradingView 7
TradingKey 7
Market source 6
MT Newswires 3
GlobeNewswire 3
Quiver Quantitative 3
dars.gov.et 3

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 16
Analyst action 5
Capital return 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
The Manila Times Direct company coverage

Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma

Molecular Partners has announced clinical progress in its Phase 2 TACTIC trial for MP0317, a drug for advanced biliary tract carcinoma (cholangiocarcinoma). The randomized study, combining MP0317 with chemoimmunotherapy, is actively recruiting patients across nine sites in France

Tone
Positive 75/100
Event
Market update
Published
16 Jul 2026 05:11
Source
The Manila Times
Quiver Quantitative Direct company coverage

Molecular Partners Highlights Bispecific Radio-DARPin Approach to Target Tumor Heterogeneity in Cancer

Molecular Partners presented its bispecific Radio-DARPin approach to target tumor heterogeneity in cancer at the Gordon Research Conference. This innovative method aims to enhance radioligand therapy (RLT) by simultaneously engaging multiple tumor markers, thereby improving treat

Tone
Positive 81/100
Event
Analyst action
Published
15 Jul 2026 04:43
Source
Quiver Quantitative
Stock Titan Direct company coverage

Molecular Partners Develops Two-Target Cancer Radiopharmaceuticals

Molecular Partners presented new data on its bispecific and multispecific Radio-DARPins at the Gordon Research Conference on Radionuclide Theranostics for the Management of Cancer. The company is developing these Radio-DARPins to address tumor heterogeneity and engage multiple ca

Tone
Positive 67/100
Event
Market update
Published
15 Jul 2026 04:43
Source
Stock Titan
Simply Wall Street Direct company coverage

European Penny Stocks To Watch In July 2026

This article identifies three European penny stocks (Piquadro, GiG Software, and Molecular Partners) with potential for investors seeking growth opportunities beyond mainstream markets. It highlights their financial health, market performance, and strategic initiatives, noting bo

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 05:39
Source
Simply Wall Street
Stock Titan Direct company coverage

Molecular Partners (NASDAQ: MOLN) details progress in Radio-DARPin cancer pipeline

Molecular Partners (MOLN) provided an update on its Radio-DARPin pipeline for cancer treatment, announcing that its lead candidate, MP0712, is in an ongoing Phase 1/2a trial with initial data expected soon and comprehensive results in 2027. The company also highlighted a compassi

Tone
Positive 65/100
Event
Earnings
Published
07 Jul 2026 10:09
Source
Stock Titan
grafa.com Direct company coverage

Molecular Partners advances MP0712 cancer trial

Molecular Partners has reported pipeline progress in its radiopharmaceutical programs, including active patient dosing in a Phase 1/2a trial for MP0712, targeting DLL3-positive small cell lung cancer and neuroendocrine tumors. Initial clinical data for MP0712 is anticipated in th

Tone
Positive 71/100
Event
Market update
Published
06 Jul 2026 13:11
Source
grafa.com
Investing.com Direct company coverage

H.C. Wainwright reiterates Molecular Partners stock rating on trial progress

H.C. Wainwright has reiterated a Buy rating and a $13.00 price target for Molecular Partners (NASDAQ:MOLN) following progress in its clinical trials. The company recently announced the first patient dosing in a Phase 1/2a trial for MP0712, a DLL3-targeted Radio-DARPin for small c

Tone
Positive 76/100
Event
Analyst action
Published
06 Jul 2026 12:11
Source
Investing.com
The Manila Times Direct company coverage

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

Molecular Partners has reported significant progress in its DARPin radiotherapeutics pipeline. Their DLL3 radiotherapy candidate, MP0712, is in Phase 1/2a clinical trials with initial data expected soon and comprehensive efficacy data in 2027. The company is also advancing MP0726

Tone
Positive 70/100
Event
Market update
Published
06 Jul 2026 05:04
Source
The Manila Times
Stock Titan Direct company coverage

Molecular Partners sees first MP0712 data in months, MP0726 imaging in H2

Molecular Partners (MOLN) announced significant progress in its Radio-DARPin therapeutics pipeline, with initial data for the MP0712 Phase 1/2a trial expected within months and broader results in 2027. The company also plans first-in-human imaging for MP0726 in H2 2026, two IND f

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 05:03
Source
Stock Titan
Stock Titan Direct company coverage

Molecular Partners (MOLN) starts first patient dosing in DLL3 Radio-DARPin MP0712 Phase 1/2a

Molecular Partners and Orano Med have announced the first patient dosing in their Phase 1/2a study of MP0712, a DLL3-targeting Radio-DARPin designed for tumors expressing DLL3, such as small cell lung cancer. The study is utilizing a "matched-pair" approach, where diagnostic imag

Tone
Positive 76/100
Event
Market update
Published
02 Jul 2026 09:40
Source
Stock Titan
Market source Direct company coverage

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712

Molecular Partners and Orano Med have announced that the first patients have been dosed in their Phase 1/2a trial for MP0712, a DLL3-targeting Radio-DARPin carrying a 212Pb therapeutic payload. This drug is designed to treat small cell lung cancer and other neuroendocrine tumors.

Tone
Positive 80/100
Event
Market update
Published
02 Jul 2026 08:00
Source
Market source
Stock Titan Direct company coverage

First patients dosed in Molecular Partners’ MP0712 DLL3 cancer trial

Molecular Partners and Orano Med have announced that the first patients have been dosed in a US multicenter Phase 1/2a trial for their DLL3-targeting, 212Pb-labelled Radio-DARPin MP0712. This program utilizes a matched-pair imaging/therapy design across five actively recruiting U

Tone
Positive 82/100
Event
Market update
Published
02 Jul 2026 04:40
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of Molecular Partners AG – MUN:6ML

This page on TradingView provides financial information specifically the enterprise value to revenue forward for Molecular Partners AG (MUN:6ML). It indicates that the market is currently closed with no trades. The content primarily serves as a data display for financial metrics

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 04:41
Source
TradingView
TradingView Direct company coverage

6ML0 Forecast — Price Target — Prediction for 2027

This article provides a price target forecast for Molecular Partners AG Sponsored ADR (6ML0) on the Frankfurt Stock Exchange for 2027. Based on 6 analysts, the current price target is 10.36, with no maximum or minimum estimates provided. It also presents data on EPS and revenue,

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 10:09
Source
TradingView
TradingView Direct company coverage

A3CSB5 Forecast — Price Target — Prediction for 2027

The article provides a price target and analyst ratings for Molecular Partners AG Sponsored ADR (A3CSB5). According to 6 analysts, the current price target is 10.36. The report also includes disclaimers that it is not investment advice and encourages users to do their own researc

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 19:40
Source
TradingView
TradingView Direct company coverage

MOLN Forecast — Price Target — Prediction for 2027

The article provides a price forecast for Molecular Partners AG (MOLN) with a target of 11.78, based on 6 analysts' 1-year predictions. It includes sections on analyst ratings, EPS, and revenue metrics, while clearly stating that the information provided is not investment advice.

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 04:10
Source
TradingView
TradingView Direct company coverage

Molecular Partners AG Actuals & Estimates (SIX:MOLN)

This article provides an overview of Molecular Partners AG (SIX:MOLN) stock, including its current price, historical performance, analyst forecasts, and company financials. It details earnings, net income, dividend policy, employee count, and offers guidance for potential investo

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:09
Source
TradingView
TradingView Direct company coverage

Molecular Partners AG Stock 12‑Month Price Target Raised to $11.78, Implies 200% Upside

The average 12-month price target for Molecular Partners AG stock has been raised to $11.78 from $10.64, according to estimates from six analysts. This updated target suggests a potential upside of approximately 200% from its June 25 closing price. The consensus rating for the st

Tone
Positive 94/100
Event
Analyst action
Published
26 Jun 2026 05:41
Source
TradingView
TradingKey Direct company coverage

Molecular Partners AG (MOLN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Molecular Partners AG (MOLN) has an earnings forecast score of 8.00, placing it 166th in the Biotechnology & Medical Research industry. Analysts provide an average price target of $13.62, with a "Buy" consensus based on 5 analysts. The company's previous quarter EPS was -$0.42, b

Tone
Positive 69/100
Event
Earnings
Published
24 Jun 2026 13:10
Source
TradingKey
TradingKey Direct company coverage

Molecular Partners AG (MOLN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Molecular Partners AG (MOLN), noting its current valuation score of 7.84, ranking 192 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -1.96, which is significantly below it

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 22:09
Source
TradingKey